WO2019196522A1 - Anticorps et procédé de modification d'anticorps - Google Patents

Anticorps et procédé de modification d'anticorps Download PDF

Info

Publication number
WO2019196522A1
WO2019196522A1 PCT/CN2019/070619 CN2019070619W WO2019196522A1 WO 2019196522 A1 WO2019196522 A1 WO 2019196522A1 CN 2019070619 W CN2019070619 W CN 2019070619W WO 2019196522 A1 WO2019196522 A1 WO 2019196522A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
region
heavy chain
fab
Prior art date
Application number
PCT/CN2019/070619
Other languages
English (en)
Chinese (zh)
Inventor
张文军
张兵
刘嘉熙
黄引娣
邱小林
Original Assignee
广州爱思迈生物医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广州爱思迈生物医药科技有限公司 filed Critical 广州爱思迈生物医药科技有限公司
Publication of WO2019196522A1 publication Critical patent/WO2019196522A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Abstract

La présente invention concerne un procédé de modification d'une région Fab d'un anticorps. En particulier, la présente invention concerne un procédé de mutation de sites particuliers d'une région charnière CH1 et d'une région CL d'un anticorps de façon à former une liaison disulfure non naturelle. La présente invention concerne en outre un anticorps produit au moyen du procédé de modification décrit et une utilisation de celui-ci.
PCT/CN2019/070619 2018-04-10 2019-01-07 Anticorps et procédé de modification d'anticorps WO2019196522A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810319413.4 2018-04-10
CN201810319413.4A CN110357960A (zh) 2018-04-10 2018-04-10 抗体及抗体改造方法

Publications (1)

Publication Number Publication Date
WO2019196522A1 true WO2019196522A1 (fr) 2019-10-17

Family

ID=68162825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/070619 WO2019196522A1 (fr) 2018-04-10 2019-01-07 Anticorps et procédé de modification d'anticorps

Country Status (2)

Country Link
CN (1) CN110357960A (fr)
WO (1) WO2019196522A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022223016A1 (fr) * 2021-04-23 2022-10-27 Chimagen Biosciences, Ltd Anticorps hétérodimères et fragment de liaison à l'antigène de ceux-ci
WO2023169559A1 (fr) * 2022-03-11 2023-09-14 Elpiscience Biopharma , Ltd. Anticorps modifiés et leurs utilisations
WO2024017371A1 (fr) * 2022-07-22 2024-01-25 信达生物制药(苏州)有限公司 Mutant favorisant l'appariement homologue de chaînes lourdes et légères d'un anticorps multispécifique

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2999756A1 (fr) * 2015-09-24 2017-03-30 The University Of North Carolina At Chapel Hill Methodes et compositions pour reduire les metastases
CN112415204B (zh) * 2020-10-23 2023-10-13 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种利用含双特异性抗体的胶体金试纸条检测细菌的方法
WO2022104692A1 (fr) * 2020-11-20 2022-05-27 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Anticorps modifié, conjugué anticorps-médicament et son utilisation
CN113045658B (zh) * 2020-12-11 2021-12-24 广州百暨基因科技有限公司 抗cll1抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106682A (zh) * 2015-08-26 2017-08-29 比森医疗股份有限公司 多特异性抗体平台和相关方法
WO2017205014A1 (fr) * 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mélanges d'anticorps

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1737890A2 (fr) * 2004-03-24 2007-01-03 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
EP2915819B1 (fr) * 2012-11-05 2019-08-14 Zenyaku Kogyo Kabushikikaisha Procédé de production d'anticorps et de composition d'anticorps
EP3148580B1 (fr) * 2014-05-29 2021-01-20 MacroGenics, Inc. Molécules de liaison tri-spécifiques se liant spécifiquement à de multiples antigènes tumoraux, et méthodes d'utilisation de celles-ci
JP6871155B2 (ja) * 2014-07-25 2021-05-12 メモリアル スローン ケタリング キャンサー センター 二重特異性ｈｅｒ２及びｃｄ３結合分子

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106682A (zh) * 2015-08-26 2017-08-29 比森医疗股份有限公司 多特异性抗体平台和相关方法
WO2017205014A1 (fr) * 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mélanges d'anticorps

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022223016A1 (fr) * 2021-04-23 2022-10-27 Chimagen Biosciences, Ltd Anticorps hétérodimères et fragment de liaison à l'antigène de ceux-ci
WO2023169559A1 (fr) * 2022-03-11 2023-09-14 Elpiscience Biopharma , Ltd. Anticorps modifiés et leurs utilisations
WO2024017371A1 (fr) * 2022-07-22 2024-01-25 信达生物制药(苏州)有限公司 Mutant favorisant l'appariement homologue de chaînes lourdes et légères d'un anticorps multispécifique

Also Published As

Publication number Publication date
CN110357960A (zh) 2019-10-22

Similar Documents

Publication Publication Date Title
WO2019196522A1 (fr) Anticorps et procédé de modification d'anticorps
AU2020201347B2 (en) Modified J-chain
TWI564306B (zh) 雙特異性抗體
EP3733715A1 (fr) Triacorps, son procédé de préparation et son utilisation
CN110551221B (zh) 一种双特异性抗体及其制备方法与应用
AU2019356573A1 (en) PD-1 single domain antibodies and therapeutic compositions thereof
US20210340273A1 (en) 5t4 single domain antibodies and therapeutic compositions thereof
US20240002503A1 (en) Novel anti-lilrb2 antibodies and derivative products
EP4039704A1 (fr) Anticorps anti-pd-1 et son utilisation
WO2019184549A1 (fr) Anticorps bispécifique et ses applications
TW202030206A (zh) 新型雙特異性cd3/cd20多肽複合物
KR20230104617A (ko) 항-덱틴-1 항체 및 이의 사용 방법
WO2020244526A1 (fr) Anticorps monoclonal anti-ceacam5 et son procédé de préparation et son utilisation
WO2022224997A1 (fr) Anticorps bispécifique anti-cldn4/anti-cd137
US20220064314A1 (en) Cd137 agonist antibodies and uses thereof
WO2022116079A1 (fr) Anticorps anti-ceacam5 humanisé et son procédé de préparation et son utilisation
JP2024503393A (ja) 抗ｐｄ－ｌ１／抗４－１ｂｂ天然抗体構造様ヘテロダイマー二重特異性抗体及びその製造方法
JP2023539645A (ja) Ｎｋｐ３０に結合する抗体分子およびその使用
WO2023006082A1 (fr) Antigène de ciblage, anti-cd16a, cellule effectrice immunitaire activant une protéine de fusion trifonctionnelle et utilisation associée
WO2023093744A1 (fr) Protéine de liaison à un antigène bispécifique
CN114773485B (zh) 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
WO2023036270A1 (fr) Ciblage d'antigène, anti-cd16a et protéine de fusion fonctionnelle d'activation de cellule effectrice immunitaire, et son utilisation
WO2023138677A1 (fr) Nouveaux anticorps anti-lag3 et produits dérivés
US20230134183A1 (en) Cldn18.2-targeting antibody, bispecific antibody and use thereof
WO2022037582A1 (fr) Anticorps bispécifique anti-cd3 et anti-cldn-18.2 et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19785445

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19785445

Country of ref document: EP

Kind code of ref document: A1